Friday, May 8, 2026
No Result
View All Result
The MEA Times
No Result
View All Result
The MEA Times
No Result
View All Result
Home Press Releases

Global In Vitro Clinical Test Equipment Market is expected to reach US$ 120.62 billion by 2031

by admin
February 20, 2025
in Press Releases
Share on FacebookShare on Twitter


(EMAILWIRE.COM, February 20, 2025 ) Global In Vitro Clinical Test Equipment market reached US$ 79.5 billion in 2023 and is expected to reach US$ 120.62 billion by 2031, growing at a CAGR of 5.35% during the forecast period 2024-2031.

Download Free Sample PDF: https://www.datamintelligence.com/download-sample/in-vitro-clinical-test-equipment-market

Market Dynamics

Rising Global Demand for Advanced Diagnostic Solutions

The increasing prevalence of both chronic and infectious diseases worldwide is a key driver of the growing demand for in vitro diagnostic (IVD) equipment. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require continuous monitoring and precise diagnostic tools to ensure effective treatment planning.

According to the World Health Organization (WHO), nearly 19 million new cancer cases were diagnosed in 2022, with 53.5 million prevalent cases recorded over a five-year period. Lung cancer led with 2.48 million cases, followed closely by breast cancer at 2.29 million. The International Agency for Research on Cancer projects that cancer incidence will rise to 21.3 million cases in 2025 and 24.1 million by 2030. Notably, breast cancer is emerging as the most widespread cancer globally, with advancements in early detection and tumor profiling technologies driving improved diagnosis and treatment outcomes.

Simultaneously, the ongoing threat of infectious diseases—including COVID-19, influenza, and newly emerging pathogens has intensified the need for rapid and accurate diagnostic solutions. Portable testing devices, such as molecular diagnostics and immunoassays, play a critical role in public health by enabling swift, reliable, and non-invasive disease detection, ultimately aiding in outbreak control and global health security.

Market Regional Share

Europe Leading the Growth in the In Vitro Clinical Test Equipment Market

Europe is experiencing the fastest growth in the in vitro clinical test equipment market, driven by a rising prevalence of chronic diseases, a well-developed healthcare system, and substantial investments in research and development. The region’s strong regulatory framework further supports the adoption of advanced diagnostic technologies, enhancing market expansion.

The increasing demand for early and accurate disease detection is further amplified by Europe’s aging population, which requires more frequent and efficient diagnostic solutions. Additionally, the presence of major medical device manufacturers, high healthcare awareness, and significant healthcare spending continue to accelerate market growth, positioning Europe as a dominant force in the industry.

Customize Your Scope: https://www.datamintelligence.com/customize/in-vitro-clinical-test-equipment-market

Market Segments

By Product Type

• Analyzers

• Consumables

• Software and Services

By Technology

• Clinical Chemistry

• Molecular Diagnostics

• Immunoassays

• Point-of-Care Testing (POCT)

• Others

By Application

• Infectious Disease Testing

• Cancer Diagnostics

• Cardiology Testing

• Endocrinology Testing

• Nephrology Testing

• Others

By End user

• Hospitals and Clinics

• Diagnostic Laboratories

• Academic and Research Institutes

• Homecare Settings

• Others

Market Key Players

Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation (Beckman Coulter, Cepheid), Mindray Bio-Medical Electronics Co., Ltd, Trivitron Healthcare, GenScript.

Emerging Players

• PerkinElmer Inc

• Agilent Technologies, Inc

• Sysmex Corporation

Recent Developments

• In September 2023, NeoDx Biotech Labs has introduced a Real-time PCR-Technology-based in vitro diagnostic kit for Ankylosing Spondylitis, enhancing healthcare services’ testing capabilities. The kit, HLA-B27 RT-PCR detection kit for Exon 2/Exon 3, detects Human Leukocyte Antigen B27 in whole blood, a key factor in inflammatory disorders like Ankylosing Spondylitis, Psoriasis, Inflammatory Bowel Disease, and Reactive Arthritis, aiding early diagnosis and treatment.



Source link

Previous Post

Global Sports Exoskeleton Market is projected to witness lucrative growth by reaching up to US$ 10,214.0 million by 2030

Next Post

The Future of Aircraft Health Monitoring: Market Growth, Innovations, and Key Trends

RelatedNews

Press Releases

Gastrointestinal Bleeding Treatment Market size to Reach USD 1.19 Billion by 2031, Supported by Minimally Invasive Care

May 7, 2026
Press Releases

$15 Billion by 2035 — How Generative AI Is Revolutionizing Video Content Creation

May 7, 2026
Press Releases

$9.8 Billion by 2035 — How Rapid Energy Storage Is Enhancing EV Performance and Regenerative Braking

May 7, 2026
Press Releases

$38.2 Billion by 2035 — How Sustainable Battery Recovery Is Powering the EV Circular Economy

May 7, 2026
Press Releases

Onboard Charger and DC Fast Charging Interoperability Test Equipment Market Analysis and Future Outlook

May 7, 2026
Press Releases

Port to Door Container Journey Orchestration Platforms Market Future Landscape

May 7, 2026
Submit a Press Release

Subscribe to our Newsletter

    Recommended

    Aurum Equity Partners and Al Nowais Group Unite to invest in Next-Generation Data Centers in Saudi Arabia

    3 years ago

    8 Years On, Infinite Ahead: BingX Launches $10M Prize Pool and Global Celebrations

    7 days ago

    Subscribe to our Newsletter

      Share Us:

      Category

      Middle East
      Europe
      Africa
      Business
      Tech
      Lifestyle
      Pres Releases

      Recent Post

      About Us

      The MEA Times reports and aggregates business, Tech and lifestyle news on EMEA regions.

      We provide press release distribution to media outlets in Africa, Middle East and Europe. Submit a press release or contact us today.

      MEA Times™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC
      No Result
      View All Result

      © 2022 - MeaTimes.com